DYN NASDAQ
Dyne Therapeutics, Inc.
1W: +4.1%
1M: +3.7%
3M: -32.5%
YTD: -8.4%
1Y: -1.1%
3Y: +133.7%
5Y: +17.5%
$16.94
+1.22 (+7.76%)
Weekly Expected Move ±7.8%
$13
$14
$16
$17
$18
Credit Risk of going bust: lower than 67% of companies Debt: 0.6% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.02 (down 99.9%), Dyne Therapeutics, Inc. would be worth roughly what it owes.
Total debt $19.9M against a stock market value of $3.16B.
Distance to default 7.09 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $12.6M (short-term plus half of long-term), stock volatility 74.9%; Altman Z'' -0.72. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.02 (down 99.9%), Dyne Therapeutics, Inc. would be worth roughly what it owes.
Total debt $19.9M against a stock market value of $3.16B.
Distance to default 7.09 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $12.6M (short-term plus half of long-term), stock volatility 74.9%; Altman Z'' -0.72. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$0.2M
Congress—
ETF Holdings—
Key Statistics
Market Cap$3.2B
52W Range14-27.31
Volume3,002,010
Avg Volume2,791,858
Beta1.12
Dividend—
Analyst Ratings
Company Info
CEOJohn G. Cox
Employees289
SectorHealthcare
IndustryBiotechnology
IPO Date2020-09-17
Websitedyne-tx.com
1560 Trapelo Road
Waltham, MA 02451
US
Waltham, MA 02451
US
781 786 8230
About Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
Latest News
Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock Rated “Moderate Buy” by Wall Street Brokerages
Dyne Therapeutics (NASDAQ:DYN) Director Brian Posner Buys 2,500 Shares of Stock
These ten healthcare stocks posted the biggest one-month losses
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 5.6% – What’s Next?
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Kerr Douglas | A-Award | 8,000 | — | 2026-10-20 |
| Kerr Douglas | A-Award | 12,000 | $16.27 | 2026-10-20 |
| Posner Brian S | P-Purchase | 2,500 | $16.00 | 2026-10-02 |
| Friedl-Naderer Johan | S-Sale | 185 | $18.88 | 2026-09-08 |
| Kerr Douglas | S-Sale | 1,290 | $18.88 | 2026-09-08 |